Related Experiment Video
Updated: Mar 14, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
ST2 and Galectin-3: Ready for Prime Time?
Wouter C Meijers1, A Rogier van der Velde1, Rudolf A de Boer1
1University Medical Center Groningen, University of Groningen , The Netherlands.
Abstract:
ST2 and galectin-3 are emerging biomarkers in the field of heart failure and have been extensively studied, and that whether they provide additional prognostic value on top of the clinical models and the gold standard in HF, (NT-pro)BNP. Our aim was to provide a comprehensive review of these emerging HF-related biomarkers in chronic, acute and incident heart failure. Regardless of the type of heart failure, both biomarkers seem to have an additional effect on top of the clinical model including natriuretic peptides. Strategies that combine multiple biomarkers may ultimately prove to be beneficial in the guidance of HF therapy in the future. However, additional prognostic value appears to be limited, and what we need is to prospectively test the consistent observations, which then might lead to the implementation of ST2 and galectin-3 in heart failure algorithms.
Related Concept Videos
Selectins
TGF - β Signaling Pathway
Proteoglycans

